Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies that can provide longer-term solutions for diabetes patients.
that it did not own to gain access to experimental cell therapies that can provide longer-term solutions for diabetes patients.
A major provider of diabetes drugs and insulin, Lilly owned nearly 8.44% stake in Sigilon as of March 27. It would pay $14.92 per share, or $34.6 million in upfront cash, for the rest of the company. Sigilon shareholders will get an additional $111.64 per share if they achieve certain developmental and regulatory milestones, Lilly said.
Shares of Sigilion soared more than eightfold in premarket trading to $34.48. The deal, which is expected to close in the third quarter of 2023, would give Lilly access to Sigilon's proprietary cell therapy candidate being developed to treat type 1 diabetes. The two companies have been partners since 2018, when Lilly paid Sigilon $63 million for a licensing deal to develop cell therapes targeting type 1 diabetes and made an undisclosed equity investment.Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Eli Lilly's weight loss drugs trounce sky-high expectations, boosting the stockThe weight loss medication market is shaping up to be a duopoly of Eli Lilly and Novo Nordisk, analysts said.
Baca lebih lajut »
Breakingviews - Eli Lilly gorges on obesity optionsEli Lilly has filled its plate with potential obesity treatments, unveiling data from two more on Monday. One offers the convenience of a pill; the other, with the scientific name retatrutide, led to patients losing an astonishing 24% of their weight at the highest dose.
Baca lebih lajut »
Eli Manning, Fanatics donate $20 million worth of merchandise to support families in needFanatics teamed up with sports personalities including Eli Manning to donate over 300,000 pieces of apparel worth about $20 million to assist 100,000 families in need.
Baca lebih lajut »
Woman in clinical trial for new weight loss drug lost 60 pounds in less than a yearThe new findings, according to Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Bariatric Center in New Orleans, are “mind-blowing.”
Baca lebih lajut »
BVTV: Lilly’s obesity splurge | Reuters VideoWatch: Eli Lilly's pipeline is full of potential obesity treatments. That’s probably merited given the market’s size. rob_cyran explains why being first to reach patients can sometimes pale in importance to having a better, or more convenient, drug:
Baca lebih lajut »
As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edgeFor now, Eli Lilly's orforglipron appears to be the top contender in the weight loss pill space due to its strong efficacy data and ease of use.
Baca lebih lajut »